The analysis of the tumor response, including the best complete response [CR], partial response [PR], and disease control rate (DCR; ideal response of CR, PR, or stable disease [SD]), median progression-free survival (PFS), examination of mesothelin expression, plasma SMRP, and immune response of anetumab-ravtansine were among the secondary objectives. Here, MSLN is linked to neoplasm.